EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access

COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application–Based Prospective Observational Cohort Study

Anna-Lena Lang iD, Nils Hohmuth iD, Vukašin Višković iD, Stefan Konigorski iD, Stefan Scholz iD, Felix Balzer iD, Cornelius Remschmidt iD, Rasmus Leistner iD

Journal of Medical Internet Research · 2024

DOI: 10.2196/47070 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Medical Internet Research, 2024. Verfasst von Anna-Lena Lang und 7 weiteren Autor:innen. Beteiligte Einrichtung: d4l Data4Life gGmbH, Potsdam, Germany. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID-19 pandemic posed significant challenges to global health systems. Efficient public health responses required a rapid and secure collection of health data to improve the understanding of SARS-CoV-2 and examine the vaccine effectiveness (VE) and drug safety of the novel COVID-19 vaccines.

Objective

This study (COVID-19 study on vaccinated and unvaccinated subjects over 16 years; eCOV study) aims to (1) evaluate the real-world effectiveness of COVID-19 vaccines through a digital participatory surveillance tool and (2) assess the potential of self-reported data for monitoring key parameters of the COVID-19 pandemic in Germany.

Methods

Using a digital study web application, we collected self-reported data between May 1, 2021, and August 1, 2022, to assess VE, test positivity rates, COVID-19 incidence rates, and adverse events after COVID-19 vaccination. Our primary outcome measure was the VE of SARS-CoV-2 vaccines against laboratory-confirmed SARS-CoV-2 infection. The secondary outcome measures included VE against hospitalization and across different SARS-CoV-2 variants, adverse events after vaccination, and symptoms during infection. Logistic regression models adjusted for confounders were used to estimate VE 4 to 48 weeks after the primary vaccination series and after third-dose vaccination. Unvaccinated participants were compared with age- and gender-matched participants who had received 2 doses of BNT162b2 (Pfizer-BioNTech) and those who had received 3 doses of BNT162b2 and were not infected before the last vaccination. To assess the potential of self-reported digital data, the data were compared with official data from public health authorities.

Results

We enrolled 10,077 participants (aged ≥16 y) who contributed 44,786 tests and 5530 symptoms. In this young, primarily female, and digital-literate cohort, VE against infections of any severity waned from 91.2% (95% CI 70.4%-97.4%) at week 4 to 37.2% (95% CI 23.5%-48.5%) at week 48 after the second dose of BNT162b2. A third dose of BNT162b2 increased VE to 67.6% (95% CI 50.3%-78.8%) after 4 weeks. The low number of reported hospitalizations limited our ability to calculate VE against hospitalization. Adverse events after vaccination were consistent with previously published research. Seven-day incidences and test positivity rates reflected the course of the pandemic in Germany when compared with official numbers from the national infectious disease surveillance system.

Conclusions

Our data indicate that COVID-19 vaccinations are safe and effective, and third-dose vaccinations partially restore protection against SARS-CoV-2 infection. The study showcased the successful use of a digital study web application for COVID-19 surveillance and continuous monitoring of VE in Germany, highlighting its potential to accelerate public health decision-making. Addressing biases in digital data collection is vital to ensure the accuracy and reliability of digital solutions as public health tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesSARS-CoV-2HumansGermanyProspective StudiesFemaleMaleMiddle AgedAdultPandemicsVaccine EfficacyAgedInternetSelf ReportYoung AdultCohort StudiesAdolescent

Stichwörter der Autor:innen

BNT162b2COVID-19COVID-19 vaccinesGermanySARS-CoV-2data collectiondigital public healthdisease surveillanceeffectivenessparticipatory disease surveillancetoolvaccinationvaccine effectivenessweb application

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • d4l Data4Life gGmbH, Potsdam, Germany.
  • Institute of Medical Informatics, Charité University Medicine Berlin, Berlin, Germany.
  • Digital Health Center, Hasso Plattner Institute for Digital Engineering, Potsdam, Germany.
  • Hasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Department of Statistics, Harvard University, Cambridge, MA, United States.
  • Health Services Research and Health Economics, Martin Luther University Halle-Wittenberg, Halle Saale, Germany.

ORCID-Profile: Anna-Lena Lang, Nils Hohmuth, Vukašin Višković, Stefan Konigorski, Stefan Scholz, Felix Balzer, Cornelius Remschmidt, Rasmus Leistner

Zitieren

APA

Lang, A. L., Hohmuth, N., Višković, V., Konigorski, S., Scholz, S., Balzer, F., Remschmidt, C., & Leistner, R. (2024). COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application–Based Prospective Observational Cohort Study. Journal of Medical Internet Research. https://doi.org/10.2196/47070

Vancouver

Lang AL, Hohmuth N, Višković V, Konigorski S, Scholz S, Balzer F, et al. COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application–Based Prospective Observational Cohort Study. Journal of Medical Internet Research. 2024. doi:10.2196/47070

BibTeX
@article{Lang2024,
  author = {Lang, Anna-Lena and Hohmuth, Nils and Višković, Vukašin and Konigorski, Stefan and Scholz, Stefan and Balzer, Felix and Remschmidt, Cornelius and Leistner, Rasmus},
  title = {COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application–Based Prospective Observational Cohort Study},
  journal = {Journal of Medical Internet Research},
  year = {2024},
  doi = {10.2196/47070}
}
Kostenlos starten →